Redeye provides an update following Acarix’s Q4 2025 report.
Redeye provides its initial take on Acarix’s Q4 report, which beat our topline estimates, while costs were somewhat higher than we had antic...
Redeye comments on today's announcement that Acarix has carried out a directed share issue of approximately SEK33.
Redeye provides an update following Acarix’s Q3 2025 report.
Redeye provides its initial take on Acarix’s Q3 report, which showed record quarterly sales driven by the company’s first order and entry in...
Redeye provides a short comment on GB-A negative decision relating to reimbursement on the German market.
Redeye provides a short comment on the recent press release announcing that the CADScor® System has received reimbursement coverage from Hea...
Redeye comments on Acarix following recent news relating to the ownership structure, where, among other things, the CEO has increased his ex...
Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the quarter.
Redeye provides its initial take on Acarix’s Q2 report, which showed a year-on-year increase in both CADScor systems installed and patches s...
Redeye views the recently announced progress on US reimbursements positively, as a second payor has agreed to provide a fixed reimbursement ...
Redeye positively views yesterday’s press release from Acarix announcing that it has secured its first major order from a leading regional d...
Redeye endorses today’s news that Acarix has secured a fixed reimbursement of USD300 for the CADScor System.
Redeye provides an update on Acarix following its Q1 report, which showed continued growth in revenues and installed systems—albeit below ou...
Redeye provides its initial take on Acarix’s Q1 report, which showed growth in both revenue and installed systems—though at a slower pace th...
Redeye endorses today’s news that Acarix was named the 2025 Digital Innovation Winner by the Global Cardiovascular Awards, which further val...
Redeye provides an update on Acarix following its year-end report, which showed softer-than-expected revenues but solid cost control.
Redeye provides its initial take on Acarix’s Q4 report, which showed revenues falling c32% short of our estimates.
Redeye updates its view on Acarix following its Q3 report, showing lower revenues than anticipated.
Redeye provides its initial take on Acarix’s Q3 report, which showed revenues falling short of estimates.
Redeye views today’s press release from Acarix as a positive development, confirming new reimbursement coverage for the CADScor System in em...
Redeye updates its view on Acarix following its Q2 2024 report.
Redeye views Acarix's Q2 as weaker than anticipated, with lower-than-expected revenues.
Yesterday after close Acarix announced a SEK21m directed share issue targeting US based family offices.
Redeye updates its view on Acarix following its Q1 report.
Redeye provides its initial take on Acarix's Q1 report.
Redeye leaves its comments following a few press releases from Acarix in the past few days.
Redeye has provided a brief comment on today's news regarding Acarix's submission of an application for cross-trading on OTCQB in the US.
Redeye updates its outlook on Acarix following its year-end report 2023.
Redeye highlights two positive developments for Acarix: a SEK33.
Redeye leaves its comments on today's news that Acarix has appointed a new CEO.
Redeye makes minor changes to its estimates following Acarix’s Q3 2023 report, which featured lower sales and costs than we had anticipated.
Redeye comments on Acarix's Q3 report which came in short of our estimates in terms of sales but due to lower costs loss was lower than expe...
Redeye comments on Acarix and adjusts its valuation following the announcement of a SEK54m fully guaranteed rights issue.
Redeye considers Acarix’s Q2 2023 report soft in terms of sales, but we see a strong operational newsflow, establishing a solid foundation f...
Redeye comments on Acarix following the recent newsflow.
Redeye leaves its comments on Acarix following the company’s Q1 2023 report.
Redeye leaves its comments on Acarix following its Q1 2023 report, which did not contain any major surprises.
Redeye comments on Acarix following the near-term announcement of two uplifting press releases, including a SEK9.
Redeye welcomes today's news that Acarix has received an important "breakthrough" order from the US Veterans Health Administration (VA).
Redeye ups its near-term sales estimates and adjusts its fair value range for Acarix following steps forward on the US market and the recent...
Redeye resumes its coverage and comments on the outcome of Acarix’s rights issue.
Redeye briefly comments on Acarix's rights issue. We pause our coverage.
Redeye leaves its comments on Acarix following the announcement of its Q2 report.
Redeye leaves its comments following today's news that Acarix has signed an additional agreement in the US and received orders from both Mis...
Redeye leaves its comments on Acarix following the announcement of its year-end report.
Company representatives from Acarix, including the new CEO, talk about the strategic plan, financial outlook, technology overview, and feedb...
Redeye leaves its view on Acarix following the announcement of its year-end report, which overall came in short of our estimates.
Redeye leaves a comment on Acarix following the release of its Q2 report.
